Small molecules and Alzheimer’s disease: Misfolding, metabolism and imaging

Current Alzheimer Research

Volumn 12, Issue 5, 2015, Pages 445-461

  Patel, Viharkumar ^a   Zhang, Xueli ^b,e   Tautiva, Nicolas A ^a   Nyabera, Akwe N ^a   Owa, Opeyemi O ^a   Baidya, Melvin ^a   Sung, Hee Chang ^a   Taunk, Pardeep S ^a   Abdollahi, Shahrzad ^a   Charles, Stacey ^a   Gonnella, Rachel A ^a   Gadi, Nikhita ^a   Duong, Karen T ^c   Fawver, Janelle N ^d   Ran, Chongzhao ^e   Jalonen, Tuula O ^a   Murray, Ian V J ^a  

^a ST GEORGE S UNIVERSITY   (Grenada)

^b SOUTHEAST UNIVERSITY   (China)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Amyloid binding; Animal models; ATP; Brain imaging; Near infrared fluorescence; Small compounds

Indexed keywords

4 PHENYLBUTYRIC ACID; ADENOSINE TRIPHOSPHATE; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; AMYLOID TAU PROTEIN; BERBERINE; BETA SECRETASE INHIBITOR; BETA SHEET BREAKER PEPTIDE; CALMIDAZOLIUM; CATECHOLAMINE; CHAPERONE; CURCUMIN; DICHLOROACETIC ACID; GLUCOSE REGULATED PROTEIN 78; GLYCOSAMINOGLYCAN; HYDRALAZINE; LY 2811376; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; METHYLENE BLUE; OLIGOMER; OXAZINE DERIVATIVE; PEPTIDE; PROTEINASE; RAPAMYCIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOOXIDATION; BETA SHEET; CITRIC ACID CYCLE; COGNITION; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; FLUORESCENCE MICROSCOPY; HUMAN; INSULIN RESISTANCE; METABOLIC DISORDER; MOLECULAR INTERACTION; MOLECULAR SENSOR; MOLECULE; NEAR INFRARED FLUORESCENCE; NEAR INFRARED IMAGING SYSTEM; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NONHUMAN; OLIGOMERIZATION; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN UNFOLDING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; ANIMAL; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; HUMANS; PROTEIN FOLDING;

EID: 84930886379     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150504145646     Document Type: Article

References (231)

1. Ladiwala AR, Dordick JS, Tessier PM. Aromatic small molecules remodel toxic soluble oligomers of amyloid b through three independent pathways. J Biol Chem 286(5): 3209-18 (2011).
2. Ho S-L, Poon C-Y, Lin C, Yan T, Kwong DWJ, Yung KKL. Inhibition of b-amyloid aggregation by albiflorin, aloeemodin and neohesperidin and their neuroprotective effect on primary hippocampal cells against b-amyloid induced toxicity. Curr Alzheimers Res 12(5): 424-433 (2015).
3. Zhai P, Xia C-L, Tan J-H, Li D, Ou T-M, Huang S-L. Syntheses and evaluation of asymmetric curcumin analogues as potential multifunctional agents for the treatment of Alzheimer's disease. Curr Alzheimers Res 12(5): 403-414 (2015).
4. Kochi A, Lee HJ, Vithanarachchi SM, Padmini V, Allen MJ, Lim MH. Inhibitory activity of curcumin derivatives towards metal-Free and metal-Induced Amyloid-b aggregation. Curr Alzheimers Res 12(5): 415-423 (2015).
5. Wong C-Y, Chung L-H, He B, Leung C-H, Ma D-L. Dual inhibition and monitoring of beta-amyloid fibrillation by a luminescent iridium(III) complex. Curr Alzheimers Res 12(5): 439- 444 (2015).
6. Chan.S.L.-F., Lam TL, Lu L, Yan SC, Leung C-H, Ma D-L. A novel tetradentate ruthenium(II) complex containing tris(2- pyridylmethyl)amine (tpa) as an inhibitor of beta-amyloid fibrillation. Curr Alzheimers Res 12(5): 434-438 (2015).
7. Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid b oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282(14): 10311-24 (2007).
8. Gonzales RM, Rlando RS. A sensitive Aβ oligomerization assay for identification of small molecule inhibitors. Open Biotechnol J 3: 108-16 (2009).
9. Cohen T, Frydman-Marom A, Rechter M, Gazit E. Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 45(15): 4727-35 (2006).
10. Shoval H, Lichtenberg D, Gazit E. The molecular mechanisms of the anti-amyloid effects of phenols. Amyloid 14(1): 73-87 (2007).
11. Petrofes Chapa RD, Emery MA, Fawver JN, Murray IV. Amyloids as Sensors and Protectors (ASAP) hypothesis. J Alzheimers Dis 29(3): 503-14 (2012).
12. Lazo ND, Grant MA, Condron MC, Rigby AC, Teplow DB. On the nucleation of amyloid b-protein monomer folding. Prot Sci 14(6): 1581-96 (2005).
13. Fezoui Y, Teplow DB. Kinetic studies of amyloid b-protein fibril assembly: differential effects of a-helix stabilization. J Biol Chem 277(40): 36948-54 (2002).
14. Arimon M, Sanz F, Giralt E, Carulla N. Template-assisted lateral growth of amyloid-b42 fibrils studied by differential labeling with gold nanoparticles. Bioconjug Chem 23(1): 27-32 (2011).
15. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 101(5): 1172-84 (2007).
16. Kheterpal I, Williams A, Murphy C, Bledsoe B, Wetzel R. Structural features of the Abeta amyloid fibril elucidated by limited proteolysis. Biochemistry 40(39): 11757-67 (2001).
17. Bieschke J, Herbst M, Wiglenda T, Friedrich RP, Boeddrich A, Schiele F, et al. Small-molecule conversion of toxic oligomers to nontoxic b-sheet-rich amyloid fibrils. Nat Chem Biol 8(1): 93-101 (2012).
18. Sun N, Funke SA, Willbold D. A Survey of Peptides with Effective Therapeutic Potential in Alzheimer's Disease Rodent Models or in Human Clinical Studies. Mini Rev Med Chem 12(5): 388-98 (2012).
19. Bush AI, Tanzi RE. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5(3): 421-32 (2008).
20. Hawkes CA, Deng LH, Shaw JE, Nitz M, McLaurin J. Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease. Eur J Neurosci 31(2): 203-13 (2010).
21. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DLM, Reiter RJ, et al. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 17(5): 1683- 90 (1997).
22. Wisniewski T, Sadowski M. Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors. BMC Neurosci 9(2): S2-S5 (2008).
23. Fawver JN, Duong KT, Wise-Scira O, Schall HE, Coskuner O, Zhu X, et al. Probing and trapping a sensitive conformation: Amyloid beta fibrils, oligomers and dimers. J Alzheimers Dis 32(1): 197-215 (2012).
24. Attar A, Ripoli C, Riccardi E, Maiti P, Li Puma DD, Liu T, et al. Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers. Brain 135(12): 3735-48 (2012).
25. Hillen H, Barghorn S, Striebinger A, Labkovsky B, Müller R, Nimmrich V, et al. Generation and therapeutic efficacy of highly oligomer-specific b-Amyloid Antibodies. J Neurosci 30(31): 10369-79 (2010).
26. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, et al. Targeting amyloid-beta peptide (A beta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A beta precursor protein (APP) transgenic mice. J Biol Chem 281(7): 4292-9 (2006).
27. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, et al. Vaccination with soluble Ab oligomers generates toxicityneutralizing antibodies. J Neurochem 79(3): 595-605 (2001).
28. Maheshwari M, Roberts JK, DeSutter B, Duong KT, Tingling J, Fawver JN, et al. Hydralazine modifies Aß fibril formation and prevents modification by lipids in vitro. Biochemistry 49(49): 10371-80 (2010).
29. Coskuner O, Murray IVJ. Adenosine triphosphate (ATP) reduces amyloid-b protein misfolding in vitro. J Alzheimers Dis 41(2): 561- 74 (2014).
30. Burcham PC, Kaminskas LM, Tan D, Pyke SM. Carbonylscavenging drugs and protection against carbonyl stress-associated cell injury. Mini Rev Med Chem 8(4): 319-30 (2008).
31. Burcham PC, Kerr PG, Fontaine FR. The antihypertensive hydralazine is an efficient scavenger of acrolein. Redox Rep 5(1): 47-9 (2000).
32. Burcham PC, Pyke SM. Hydralazine inhibits rapid acroleininduced protein oligomerization: role of aldehyde scavenging and adduct trapping in cross-link blocking and cytoprotection. Mol Pharmacol 69(3): 1056-65 (2006).
33. Galvani S, Coatrieux C, Elbaz M, Grazide MH, Thiers JC, Parini A, et al. Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic Biol Med 45(10): 1457-67 (2008).
34. Vuddanda PR, Chakraborty S, Singh S. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin Invest Drugs 19(10): 1297-307 (2010).
35. Williams AD, Sega M, Chen M, Kheterpal I, Geva M, Berthelier V, et al. Structural properties of Ab protofibrils stabilized by a small molecule. Proc Natl Acad Sci USA 102(20): 7115-20 (2005).
36. Exley C, Korchazhkina OV. Promotion of formation of amyloid fibrils by aluminium adenosine triphosphate (AlATP). J Inorganic Biochem (3GÇô4): 215-24 (2001).
37. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-[beta] attenuates Alzheimerdisease- like pathology in the PDAPP mouse. Nature 400(6740): 173-7 (1999).
38. Caesar I, Jonson M, Nilsson KP, Thor S, Hammarström P. Curcumin promotes A-beta fibrillation and reduces neurotoxicity in transgenic Drosophila. PLoS ONE 7(2): e31424 (2012).
39. Necula M, Breydo L, Milton S, Kayed R, van der Veer WE, Tone P, et al. Methylene blue Inhibits Amyloid Ab oligomerization by promoting fibrillization. Biochemistry 46(30): 8850-60 (2007).
40. McKoy AF, Chen J, Schupbach T, Hecht MH. A novel inhibitor of amyloid b (ab) peptide aggregation: from high throughput screening to efficacy in an animal model of alzheimer disease. J Biol Chem 287(46): 38992-9000 (2012).
41. Putcha D, Brickhouse M, O'Keefe K, Sullivan C, Rentz D, Marshall G, et al. Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in nondemented elderly adults. J Neurosci 31(48): 17680-8 (2011).
42. Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, et al. Alterations in memory networks in mild cognitive ompairment and Alzheimer's disease: An independent component analysis. J Neurosci 26(40): 10222-31 (2006).
43. Fogel H, Frere S, Segev O, Bharill S, Shapira I, Gazit N, et al. APP homodimers transduce an amyloid-b-mediated increase in release probability at excitatory synapses. Cell Reports 7(5): 1560-76 (2014).
44. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I. Amyloid-b as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 12(12): 1567-76 (2009).
45. Majumdar A, Cesario W, White-Grindley E, Jiang H, Ren F, Khan M, et al. Critical role of amyloid-like oligomers of drosophila Orb2 in the persistence of memory. Cell 148(3): 515-29 (2012).
46. Heinrich SU, Lindquist S. Protein-only mechanism induces selfperpetuating changes in the activity of neuronal Aplysia cytoplasmic polyadenylation element binding protein (CPEB). Proc Natl Acad Sci USA 108(7): 2999-3004 (2011).
47. Chalermpalanupap T, Kinkead B, Hu W, Kummer M, Hammerschmidt T, Heneka M, et al. Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. Alzheimer's Res Ther 5(2): 21 (2013).
48. Muresan Z, Muresan V. Seeding neuritic plaques from the distance: a possible role for brainstem neurons in the development of alzheimer's disease pathology. Neurodegen Dis 5(3-4): 250-8 (2008).
49. Bindoli A, Rigobello MP, Deeble DJ. Biochemical and toxicological properties of the oxidation-products of catecholamines. Free Radic Biol Med 13(4): 391-405 (1992).
50. Bindoli A, Scutari G, Rigobello M. The role of adrenochrome in stimulating the oxidation of catecholamines. Neurotox Res 1(2): 71-80 (1999).
51. da Silva GF, Ming LJ. Metallo-ROS in Alzheimer's disease: Oxidation of neurotransmitters by CuII-b-Amyloid and neuropathology of the disease. Agnew Chem Int Ed Engl 46(18): 3337-41(2007).
52. Huong VT, Shimanouchi T, Shimauchi N, Yagi H, Umakoshi H, Goto Y, et al. Catechol derivatives inhibit the fibril formation of amyloid-b peptides. J Biosci Bioeng 109(6): 629-34 (2010).
53. Lashuel HA, Hartley DM, Balakhaneh D, Aggarwal A, Teichberg S, Callaway DJE. New class of inhibitors of amyloid-b fibril formation: implications for the mechanism of pathogenesis in alzheimer's disease. J Biol Chem 277(45):42881-90 (2002).
54. Fu W, Luo H, Parthasarathy S, Mattson MP. Catecholamines potentiate Amyloid b-peptide neurotoxicity: Involvement of oxidative stress, mitochondrial dysfunction, and perturbed calcium homeostasis. Neurobiol Dis 5(4): 229-43 (1998).
55. German DC, Nelson O, Liang F, Liang CL, Games D. The PDAPP mouse model of Alzheimer's disease: Locus coeruleus neuronal shrinkage. J Comp Neurol 492(4): 469-76 (2005).
56. Fitzgerald PJ. Is Elevated Norepinephrine an Etiological Factor in Some Cases of Alzheimers Disease? Curr Alzheimers Res 7(6): 506-16 (2010).
57. Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci USA 107(13): 6058-63 (2010).
58. Kalinin S, Gavrilyuk V, Polak PE, Vasser R, Zhao J, Heneka MT, et al. Noradrenaline deficiency in brain increases b-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging 28(8): 1206-14 (2007).
59. Conway KA, Rochet JC, Bieganski RM, Lansbury PT. Kinetic stabilization of the a-synuclein protofibril by a dopamine-asynuclein adduct. Science 294(5545): 1346-9 (2001).
60. Si K, Choi YB, White-Grindley E, Majumdar A, Kandel ER. Aplysia CPEB can form prion-like multimers in sensory neurons that contribute to long-term facilitation. Cell 140(3): 421-35 (2010).
61. O'Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 99(3): 1485-90 (2002).
62. Kayed R, Head E, Sarsoza F, Saing T, Cotman C, Necula M, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2(1): 18 (2007).
63. Moss RJ, Mastri AR, Schut LJ. The coexistence and differentiation of late onset Huntington's disease and Alzheimer's disease. A case report and review of the literature. J Am Geriatr Soc 36(3): 237-41 (1988).
64. Soto C, Castaño EM, Prelli F, Asok Kumar R, Baumann M. Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, Gelsolin and AA amyloids. FEBS Lett 371(2): 110-4 (1995).
65. Fernandez-Alonso J, Rios-Camacho C, Valenzuela-Castaño A, Hernanz-Mediano W. Mixed systemic amyloidosis in a patient receiving long term haemodialysis. J Clin Pathol 47(6): 560-1 (1994).
66. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J, et al. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and Prion diseases. J Neurosci 30(13): 4528-35 (2010).
67. Popescu A, Lippa CF, Lee VMY, Trojanowski JQ. Lewy bodies in the amygdala: increase of α-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol-Chicago 61(12): 1915-9 (2004).
68. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619): 636-40 (2003).
69. Lee VMY, Giasson BI, Trojanowski JQ. More than just two peas in a pod: common amyloidogenic properties of tau and a-synuclein in neurodegenerative diseases. Trends Neurosci 27(3): 129-34 (2004).
70. Kayed R, Glabe CG. Conformation-dependent anti-amyloid oligomer antibodies. Method Enzymol 413: 326-44 (2006).
71. Chien V, Atiken JF, Zhang S, Buchanan CM, Hickey A, Brittain T, et al. The chaperone proteins HSP70, HSP40/DnaJ and GRP78/BiP suppress misfolding and formation of b-sheet-containing aggregates by human amylin: a potential role for defective chaperone biology in Type 2 diabetes. Biochem J 432(1): 113-21 (2010).
72. Yoshiike Y, Minai R, Matsuo Y, Chen YR, Kimura T, Takashima A. Amyloid oligomer conformation in a group of natively folded proteins. PLoS ONE 3(9): e3235 (2008).
73. Gorbatyuk MS, Gorbatyuk OS. The molecular chaperone GRP78/BiP as a therapeutic target for neurodegenerative disorders: a mini review. J Genet Syndrome Gene Ther 4(2): 182 (2013).
74. Hoozemans JJM, Veerhuis R, Van Haastert ES, Rozemuller JM, Baas F, Eikelenboom P, et al. The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol 110(2): 165-72 (2005).
75. Quinones QJ, deRidder GG, Pizzo SV. GRP78: A chaperone with diverse roles beyond the endoplasmic reticulum. Histol Histopathol 23(11): 1409-16 (2008).
76. Yang Y, Turner RS, Gaut JR. The chaperone BiP/GRP78 binds to amyloid precursor protein and decreases Ab40 and Ab42 secretion. J Biol Chem 273(40): 25552-5 (1998).
77. Hoshino T, Nakaya T, Araki W, Suzuki K, Suzuki T, Mizushima T. Endoplasmic reticulum chaperones inhibit the production of amyloid-b peptides. Biochem J 402(3): 581-589 (2012).
78. Kakimura J, Kitamura Y, Takata K, Tsuchiya D, Taniguchi T, Gebicke-Haerter PJ, et al. Possible involvement of ER chaperone Grp78 on reduced formation of amyloid-b deposits. Ann NY Acad Sci 977(1): 327-32 (2002).
79. Ferriera IL, Resende R, Ferriero E, Rego AC, Periera CF. Multiple defects in energy metabolism in Alzheimers disease. Curr Drug Target 11(10): 1193-206 (2010).
80. Zhang C, Rissman RA, Feng J. Characterization of ATP alternations in an Alzheimer's disease transgenic mouse model. J Alzheimers Dis 44(2): 375-8 (2015).
81. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimers Res 4(2): 147-52 (2007).
82. Craft S, Cholerton B, Baker LD. Insulin and Alzheimer's Disease: Untangling the web. J Alzheimers Dis 33(0): S263-S275 (2013).
83. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetesevidence reviewed. J Diabetes Sci Technol 2(6):1101-13 (2008).
84. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimers Res 9(1): 35-66 (2012).
85. Murray IVJ, Proza JF, Sohrabji F, Lawler JM. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp Biol Med (Maywood) 236(7): 772-82 (2011).
86. Parihar MS, Brewer GJ. Mitoenergetic failure in Alzheimer disease. Am J Physiol - Cell Physiol 292(1): C8-C23 (2007).
87. de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Reports 42(8): 475-81 (2009).
88. Perry G, Nunomura A, Raina AK, Aliev G, Siedlak SL, Harris PLR, et al. A metabolic basis for Alzheimer disease. Neurochem Res 28(10): 1549-52 (2003).
89. Salkovic-Petrisic M, Osmanovic J, Grünblatt E, Riederer P, Hoyer S. Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-β. J Alzheimers Dis 18(4): 729-50 (2009).
90. Bell R, Zlokovic B. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118(1): 103-13 (2009).
91. Baquer N, Taha A, Kumar P, McLean P, Cowsik S, Kale R, et al. A metabolic and functional overview of brain aging linked to neurological disorders. Biogerontology 10(4): 377-413 (2009).
92. Dimou E, Booij J, Rodrigues M, Prosch H, Attems J, Knoll P, et al. Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. Curr Alzheimers Res 6(3): 312-9 (2009).
93. Gibson GE, Starkov A, Blass JP, Ratan RR, Beal MF. Cause and consequence: Mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochem Biophys Acta- Mol Basis Dis 1802(1): 122-34 (2010).
94. Gibson GE, Karuppagounder SS, Shi Q. Oxidant-induced changes in mitochondria and calcium dynamics in the pathophysiology of Alzheimer's disease. Ann NY Acad Sci 1147(1): 221-32 (2008).
95. Xiong K, Cai H, Luo XG, Struble R, Clough R, Yan XX. Mitochondrial respiratory inhibition and oxidative stress elevate bsecretase (BACE1) proteins and activity in vivo in the rat retina. Exp Brain Res 181(3): 435-46 (2007).
96. Arias C, Montiel T, Quiroz-Báez R, Massieu L. β-Amyloid neurotoxicity is exacerbated during glycolysis inhibition and mitochondrial impairment in the rat hippocampus in vivo and in isolated nerve terminals: implications for Alzheimer's disease. Exp Neurol 176(1): 163-74 (2002).
97. Velliquette RA, O'Connor T, Vassar R. Energy inhibition elevates β-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 25(47): 10874-83 (2005).
98. O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, et al. Phosphorylation of the translation initiation factor eIF2a increases BACE1 levels and promotes amyloidogenesis. Neuron 60(6): 988-1009 (2008).
99. Karuppagounder SS, Xu H, Shi Q, Chen LH, Pedrini S, Pechman D, et al. Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol Aging 30(10): 1587-600 (2009).
100. Chen Y, Liang Z, Blanchard J, Dai CL, Sun S, Lee M, et al. A nontransgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol 47(2): 711-25 (2013).
101. Dodart JC, Mathis C, Bales KR, Paul SM, Ungerer A. Early regional cerebral glucose hypometabolism in transgenic mice overexpressing the V717F β-amyloid precursor protein. Neurosci Lett 277(1): 49-52 (1999).
102. Soucek T, Cumming R, Dargusch R, Maher P, Schubert D. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron 39(1): 43-56 (2003).
103. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22(1): 246-60 (2008).
104. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, et al. Ab oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282(15): 11590-601 (2007).
105. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 106(34): 14670-5 (2009).
106. de la Monte SM, Wands JR. Alzheimer's Disease is type 3 diabetes-Evidence reviewed. J Diab Sci Techol 2(6): 1101-13 (2008).
107. Yan LJ, Xiao M, Chen R, Cai Z. Metabolic dysfunction of astrocyte: an initiating factor in β-amyloid pathology? Aging Neurodegeneration 1(1): 7-14 (2013).
108. Chakrabarti A, Chen AW, Varner JD. A review of the mammalian unfolded protein response. Biotechnol Bioeng 108(12): 2777-93 (2011).
109. Lee DY, Lee KS, Lee HJ, Kim DH, Noh YH, Yu K, et al. Activation of PERK signaling attenuates Ab-mediated ER stress. PLoS ONE 5(5): e10489 (2010).
110. Doyle KM, Kennedy D, Gorman AM, Gupta S, Healy SJ, Samali A. Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J Cell Mol Med 15(10): 2025-39 (2011).
111. Katayama T, Imaizumi K, Manabe T, Hitomi J, Kudo T, Tohyama M. Induction of neuronal death by ER stress in Alzheimer's disease. J Chem Neuroanat 28(1-2): 67-78 (2004).
112. Nishitsuji K, Tomiyama T, Ishibashi K, Ito K, Teraoka R, Lambert MP, et al. The E693D mutation in amyloid precursor protein increases intracellular accumulation of amyloid b oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. Am J Pathol 174(3): 957-69 (2009).
113. Endres K, Reinhardt S. ER-stress in Alzheimer's disease: turning the scale? Am J Neurodegener Dis 2(4): 247-65 (2013).
114. Salminen A, Kauppinen A, Suuronen T, Kaarniranta K, Ojala J. ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology. J Neuroinflam 6(1): 41 (2009).
115. Wiley JC, Pettan-Brewer C, Ladiges WC. Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice. Aging Cell 10(3): 418-28 (2011).
116. Dioísio PA, Amaral JD, Ribeiro MF, Lo AC, D'Hooge R, Rodrigues ClMP. Amyloid-b pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. Neurobiol Aging 6(1): 228-40 (2015).
117. Kaufman RJ, Scheuner D, Schroder M, Shen X, Lee K, Liu CY, et al. The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol 3(6): 411-21 (2002).
118. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trend Biochem Sci 26(8): 504-10 (2001).
119. Özcan U, Yilmaz E, Özcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of Type 2 diabetes. Science 313(5790): 1137-40 (2006).
120. Chadwick W, Mitchell N, Martin B, Maudsley S. Therapeutic targeting of the endoplasmic reticulum in Alzheimer's disease. Curr Alzheimers Res 9(1): 110-9 (2012).
121. Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Trans Med 5(206): 206ra138 (2013).
122. Qin L, Wang Z, Tao L, Wang Y. ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. Autophagy 6(2): 239-47 (2010).
123. André C, Cota D. Coupling nutrient sensing to metabolic homoeostasis: the role of the mammalian target of rapamycin complex 1 pathway. Proc Nutr Soc 71(04): 502-10 (2012).
124. Rikiishi H. Novel Insights into the Interplay between Apoptosis and Autophagy. Int J Cell Biol 2012: 317645 (2012).
125. Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta (BBA) - Mol Cell Res 1833(12): 3448-59 (2013).
126. Altman BJ, Rathmell JC. Metabolic stress in autophagy and cell death pathways. Cold Spring Harbor Perspect Biol 4(9): a008763 (2012).
127. Yang DS, Kumar A, Stavrides P, Peterson J, Peterhoff CM, Pawlik M, et al. Neuronal apoptosis and autophagy cross talk in aging PS/APP mice, a model of Alzheimer's disease. Am J Pathol 173(3): 665-81 (2008).
128. Funderburk SF, Marcellino BK, Yue Z. Cell "self-eating" (autophagy) mechanism in Alzheimer's disease. Mt Sinai J Med 77(1): 59-68 (2010).
129. Cai Z, Yan LJ. Rapamycin, Autophagy, and Alzheimer's Disease. J Biochem Pharmacol Res 1(2): 84-90 (2013).
130. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), Amyloid-β, and Tau. J Biol Chem 285(17): 13107-20 (2010).
131. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-b levels in a mouse model of Alzheimer's disease. PLoS ONE 2010 5(4): e9979 (2010).
132. Tyedmers J, Madariaga ML, Lindquist S. Prion switching in response to environmental stress. PLoS Biol 6(11): e294 (2008).
133. Fawver JN, Schall HE, Petrofes-Chapa RD, Zhu X, Murray IVJ. Amyloid-β metabolite sensing: Biochemical linking of glycation modification and misfolding. J Alzheimers Dis 30(1): 63-73 (2012).
134. Lau FC, Shukitt-Hale B, Joseph JA. Nutritional intervention in brain aging: reducing the effects of inflammation and oxidative stress. Subcell Biochem 42: 299-318 (2007).
135. Bresden DE. Reversal of cognitive decline: a novel therapeutic program. Aging 6(9): 707-17 (2014).
136. Sun J, Feng X, Liang D, Duan Y, Lei H. Down-regulation of energy metabolism in Alzheimer's disease is a protective response of neurons to the microenvironment. J Alzheimers Dis 28(2): 389- 402 (2012).
137. Galluzzi L, Kepp O, Heiden MGV, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 12(11): 829-46 (2013).
138. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10(4): 267-77 (2010).
139. Salani B, Rio AD, Marini C, Sambuceti G, Cordera R, Maggi D. Metformin, cancer and glucose metabolism. Endocr-Relat Cancer 21(6): R461-R471 (2014).
140. Moreira PI. Metformin in the diabetic brain: friend or foe? Ann Trans Med 2(6): 54 (2014).
141. Li J, Deng J, Sheng W, Zuo Z. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav 101(4): 564-74 (2012).
142. Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: A populationbased case-control study. J Am Geriatr Soc 60(5): 916-21 (2012).
143. Schubert D. Glucose metabolism and Alzheimer's disease. Ageing Res Rev 4(2): 240-57 (2005).
144. Martins RN, Harper CG, Stokes GB, Masters CL. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 46(4): 1042-5 (1986).
145. Russell RL, Siedlak SL, Raina AK, Bautista JM, Smith MA, Perry G. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch Biochem Biophys 370(2): 236-9 (1999).
146. Newington JT, Pitts A, Chien A, Arseneault R, Schubert D, Cumming RC. Amyloid β resistance in nerve cell lines is mediated by the Warburg effect. PLoS One 6(4): e19191 (2011).
147. Kankotia S, Stacpoole PW. Dichloroacetate and cancer: New home for an orphan drug? Biochim Biophys Acta (BBA) - Reviews on Cancer 1846(2): 617-29 (2015).
148. Atamna H, Kumar R. Protective role of mBlue in Alzheimer's disease via mitochondria and cytochrome c oxidase. J Alzheimers Dis 20: 439-52 (2010).
149. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol 96(1): 32-45 (2012).
150. Anderson L, Wittkopp SM, Painter CJ, Liegel JJ, Schreiner R, Bell JA, et al. What is happening when the blue bottle bleaches: An investigation of the methylene blue-catalyzed air oxidation of glucose. J Chem Educ 89(11): 1425-31 (2012).
151. Crowe A, James MJ, Lee VMY, Smith AB, Trojanowski JQ, Ballatore C, et al. Aminothienopyridazines and methylene blue affect tau fibrillization via cysteine oxidation. J Biol Chem 288(16): 11024-37 (2013).
152. Akoury E, Pickhardt M, Gajda M, Biernat J, Mandelkow E, Zweckstetter M. Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Agnew Chem Int Ed Engl 52(12): 3511-5 (2013).
153. Lira-De León KI, GarcÍa-Gutiérrez P, Serratos IN, Palomera- Cárdenas M, Figueroa-Corona M, Campos-Peña V, et al. Molecular mechanism of tau aggregation induced by anionic and cationic dyes. J Alzheimers Dis 35(2): 319-34 (2013).
154. Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 280: 7614 (2005).
155. Mori T, Koyama N, Segawa T, Maeda M, Maruyama N, Kinoshita N, et al. Methylene blue modulates b-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice. J Biol Chem 289(44): 30303-17 (2014).
156. Paban V, Manrique C, Filali M, Maunoir-Regimbal S, Fauvelle F, Alescio-Lautier B. Therapeutic and preventive effects of methylene blue on Alzheimer's disease pathology in a transgenic mouse model. Neuropharmacol 76 Part A: 68-79 (2014).
157. Wischik CM, Bentham P, Wischik DJ, Seng KM. O3-04-07: Tau aggregation inhibitor (TAI) therapy with RemberTM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 4(4): poster T167 (2008).
158. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3(3): 186-91 (2007).
159. Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Discov 6(5): 341-2 (2007).
160. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17(9): 1060-5 (2011).
161. Bredesen DE, John V. Next generation therapeutics for Alzheimer's disease. EMBO Mol Med 5(6): 795-8 (2013).
162. Van Eldik LJ, Koppal T, Watterson DM. Barriers to alzheimer disease drug discovery and development in academia. Alzheimer Dis Assoc Disord 16: S18-S28 (2002).
163. Contag PR. Whole-animal cellular and molecular imaging to accelerate drug development. Drug Discov Today 7(10): 555-62 (2002).
164. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov 7(7): 591-607 (2008).
165. Nordberg A. Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther 3(6): 34 (2011).
166. Rudin M. Noninvasive structural, functional, and molecular imaging in drug development. Curr Opin Chem Biol 13(3): 360-71 (2009).
167. Niu G, Chen X. Has molecular and cellular imaging enhanced drug discovery and drug development? Drugs in R&D 9(6): 351-68 (2008).
168. Jakob-Roetne R, Jacobsen H. Alzheimer's disease: from pathology to therapeutic approaches. Agnew Chem Int Ed Engl 48(17): 3030- 59 (2009).
169. Chang WM, Dakanali M, Capule CC, Sigurdson CJ, Yang J, Theodorakis EA. ANCA: A family of fluorescent probes that bind and stain amyloid plaques in human tissue. ACS Chem Neurosci 2(5): 249-55 (2011).
170. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18f-av-AV45: a PET agent for Abeta plaques in the brain. J Nuc Med 50(11): 1887-94 (2009).
171. Li Q, Lee JS, Ha C, Park CB, Yang G, Gan WB, et al. Solid-phase synthesis of styryl dyes and their application as amyloid sensors. Angew Chem Int Ed 43(46): 6331-5 (2004).
172. Hintersteiner M, Enz A, Frey P, Jaton AL, Kinzy W, Kneuer R, et al. In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol 23(5): 577-83 (2005).
173. Cui M, Ono M, Kimura H, Liu B, Saji H. Synthesis and structureaffinity relationships of novel dibenzylideneacetone derivatives as probes for b-amyloid plaques. J Med Chem 54(7): 2225-40 (2011).
174. Ono M, Watanabe H, Kimura H, Saji H. BODIPY-based molecular probe for imaging of cerebral b-amyloid plaques. ACS Chem Neurosci 3(4): 319-24 (2012).
175. Ran C, Zhao W, Moir RD, Moore A. Non-conjugated small molecule FRET for differentiating monomers from higher molecular weight amyloid beta species. PLoS ONE 6(4): e19362 (2011).
176. Zhang X, Tian Y, Li Z, Tian X, Sun H, Liu H, et al. Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid β species in Alzheimer's disease. J Am Chem Soc 135(44): 16397-409 (2013).
177. Zhang X, Ran C. Dual functional small molecule probes as fluorophore and ligand for misfolding proteins. Curr Org Chem 17: 580-593 (2013).
178. Cui M. Past and recent progress of molecular imaging probes for bamyloid plaques in the brain. Curr Med Chem 21(1): 82-112 (2014).
179. Eckroat TJ, Mayhoub AS, Garneau-Tsodikova S. Amyloid-β probes: Review of structure-activity and brain-kinetics relationships. Beilstein J Organ Chem 9: 1012-44 (2013).
180. Nesterov EE, Skoch J, Hyman BT, Klunk WE, Bacskai BJ, Swager TM. In vivo optical imaging of amyloid aggregates in brain: Design of fluorescent markers. Agnew Chem Int Ed Engl 44(34): 5452-6 (2005).
181. Cui M, Ono M, Watanabe H, Kimura H, Liu B, Saji H. Smart nearinfrared fluorescence probes with donor-acceptor structure for in vivo detection of β-amyloid deposits. J Am Chem Soc 136(9): 3388-94 (2014).
182. Fu H, Cui M, Tu P, Pan Z, Liu B. Evaluation of molecules based on the electron donor-acceptor architecture as near-infrared bamyloidal- targeting probes. Chem Commun (Cambridge, England) 50(80): 11875-8 (2014).
183. Okamura N, Mori M, Furumoto S, Yoshikawa T, Harada R, Ito S, et al. In vivo detection of amyloid plaques in the mouse brain using the near-infrared fluorescence probe THK-265. J Alzheimers Dis 23(1): 37-48 (2011).
184. Zhang X, Tian Y, Yuan P, Li Y, Yaseen MA, Grutzendler J, et al. A bifunctional curcumin analogue for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer's disease. Chem Commun 50(78): 11550-3 (2014).
185. Zhang X, Tian Y, Tian X, Ross A, Moir R, Moore A, et al. Design and synthesis of curcumin analogues as imaging and therapeutic agents for alzheimer's disease. World Mol Imag Congr Seoul Korea 2014;2014(Poster).
186. Jameson LP, Dzyuba SV. Aza-BODIPY: improved synthesis and interaction with soluble Ab1-42 oligomers. Bioorg Med Chem Lett 23(6): 1732-5 (2013).
187. Heo CH, Kim KH, Kim HJ, Baik SH, Song H, Kim YS, et al. A two-photon fluorescent probe for amyloid-b plaques in living mice. Chem Commun (Cambridge, England) 49(13): 1303-5 (2013).
188. Tian Y, Zhang X, Li Y, Shoup T, Elmaleh D, Moore A, et al. Crown ethers attenuate aggregation of amyloid beta of Alzheimer's disease. Chem Commun 50(99) :15792-5 (2014).
189. Yang W, Wong Y, Ng OTW, Bai LP, Kwong DWJ, Ke Y, et al. Inhibition of β-amyloid peptide aggregation by multifunctional carbazole-based fluorophores. Angew Chem Int Ed 51(8): 1804-10 (2012).
190. Harada R, Okamura N, Furumoto S, Yoshikawa T, Arai H, Yanai K, et al. Use of a benzimidazole derivative BF-188 in fluorescence multispectral imaging for selective visualization of tau protein fibrils in the Alzheimer's disease brain. Mol Imaging Biol 16(1): 19-27 (2014).
191. Cook NP, Torres V, Jain D, Martí AA. Sensing amyloid-b aggregation using luminescent dipyridophenazine ruthenium(II) complexes. J Am Chem Soc 133(29): 11121-3 (2011).
192. Watanabe H, Ono M, Matsumura K, Yoshimura M, Kimura H, Saji H. Molecular imaging of β-amyloid plaques with near-infrared boron dipyrromethane (BODIPY)-based fluorescent probes. Mol Imaging 12(5): 338-47 (2013).
193. Ran C, Moore A. Spectral unmixing imaging of wavelengthresponsive fluorescent probes: an application for the real-time report of amyloid Beta species in Alzheimer's disease. Mol Imaging Biol 14(3): 293-300 (2012).
194. Hardy J, Selkoe DJ. The Amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297(5580): 353 (2002).
195. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Ab elevation, and amyloid plaques in transgenic mice. Science 274(5284): 99-103 (1996).
196. Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 282(50): 36275-82 (2007).
197. Masuda Y, Fukuchi M, Yatagawa T, Tada M, Takeda K, Irie K, et al. Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid b-protein fibrils. Bioorg Med Chem 19(20): 5967-74 (2011).
198. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24(3): 516-24 (2006).
199. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci 31(46): 16507-16 (2011).
200. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451(7179): 720-4 (2008).
201. Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 7(11): 1181-3 (2004).
202. Condello C, Schain A, Grutzendler J. Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci Rep 1: 19 (2011).
203. Xie H, Hou S, Jiang J, Sekutowicz M, Kelly J, Bacskai BJ. Rapid cell death is preceded by amyloid plaque-mediated oxidative stress. Proc Natl Acad Sci USA 110(19): 7904-9 (2013).
204. Xie H, Guan J, Borrelli LA, Xu J, Serrano-Pozo A, Bacskai BJ. Mitochondrial alterations near amyloid plaques in an Alzheimer's disease mouse model. J Neurosci 33(43): 17042-51 (2013).
205. Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang Gf, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-b ligand in transgenic mice. Proc Natl Acad Sci USA 100(21): 12462-7 (2003).
206. Murugan NA, Zalesny R, Kongsted J, Nordberg A, Âgren H. Promising two-photon probes for in vivo detection of β amyloid deposits. Chem Commun (Cambridge, England) 50(79): 11694-7 (2014).
207. Farrar CT, William CM, Hudry E, Hashimoto T, Hyman BT. RNA aptamer probes as optical imaging agents for the detection of amyloid plaques. PLoS ONE 9(2): e89901 (2014).
208. Staderini M, Aulic S, Bartolini M, Tran HNA, Gonzàlez-Ruiz V, Pérez DI, et al. A fluorescent styrylquinoline with combined therapeutic and diagnostic activities against Alzheimer's and prion diseases. ACS Med Chem Lett 4(2): 225-9 (2013).
209. Cook NP, Archer CM, Fawver JN, Schall HE, Rodriguez-Rivera J, Dineley KT, et al. Ruthenium red colorimetric and birefringent staining of amyloid-ß aggregates in vitro and in Tg 2576 mice. ACS Chem Neurosci 4(3): 379-84 (2013).
210. Cao K, Farahi M, Dakanali M, Chang WM, Sigurdson CJ, Theodorakis EA, et al. Aminonaphthalene 2-cyanoacrylate (ANCA) probes fluorescently discriminate between amyloid-b and prion plaques in brain. J Am Chem Soc 134(42): 17338-41 (2012).
211. Honson NS, Johnson RL, Huang W, Inglese J, Austin CP, Kuret J. Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis 28(3): 251-60 (2007).
212. Siclovan T, Montalto M, Lam T, Agdeppa E, Williams A, Hehir C. Tan Agents for imaging soluble α-β. US7727511 B2 2010.
213. Wong HE, Kwon I. Xanthene food dye, as a modulator of Alzheimer's disease amyloid-beta peptide aggregation and the associated impaired neuronal cell function. PLoS ONE 6: e25752 (2011).
214. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488(7409): 96-9 (2012).
215. Abbott A. Neuroscience: The plaque plan. Nature 456(7219): 161-4 (2008).
216. Giacobini E, Gold G. Alzheimer disease therapy--moving from amyloid-β to tau. Nat Rev Neurol 9(12): 677-86 (2013).
217. Castellani RJ, Lee HG, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, et al. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-β. J Alzheimers Dis 18(2): 447-52 (2009).
218. Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, et al. Human LilrB2 is a b-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science (New York, N Y) 341(6152): 1399-404 (2013).
219. Varghese J. Bace: Lead target for orchestrated therapy of Alzheimer's disease. USA: Wiley 2010.
220. Mathis CA, Mason NS, Lopresti BJ, Klunk WE. Development of positron emission tomography b-amyloid plaque imaging agents. Sem Nucl Med 42(6): 423-32 (2012).
221. Zhang L, Chang RC-C, Chu LW, Mak HK-F. Current neuroimaging techniques in Alzheimer's disease and applications in animal models. Am J Nucl Med Mol Imaging 2(3): 386-404 (2012).
222. Kuntner C, Kesner AL, Bauer M, Kremslehner R, Wanek T, Mandler M, et al. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imaging Biol 11(4): 236- 40 (2009).
223. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 27(41): 10957-68 (2007).
224. Poisnel G, Dhilly M, Moustié O, Delamare J, Abbas A, Guilloteau D, et al. PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol Aging 33(11): 2561-71 (2012).
225. Manook A, Ousefi BH, Willuweit A, Platzer S, Reder S, Voss A, et al. Small-animal PET imaging of amyloid-β plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS ONE 7(3): e31310 (2012).
226. Jack CR, Garwood M, Wengenack TM, Borowski B, Curran GL, Lin J, et al. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med 52(6): 1263-71 (2004).
227. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with pittsburgh compound-B. Ann Neurol 55(3): 306-19 (2004).
228. Higuchi M, Iwata N, Matsuba Y, Sato K, Sasamoto K, Saido TC. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 8(4): 527-33 (2005).
229. Nordberg A, Rinne JO, Kadir A, Långström B. The use of PET in Alzheimer disease. Nat Rev Neurol 6(2): 78-87 (2010).
230. Reardon S. Pharma firms join NIH on drug development. Nature 2014;November:doi:10.1038/nature.2014.14672.
231. Ivinson AJ, Lane R, May PC, Hosford DA, Carrillo MC, Siemers ER. Partnership between academia and industry for drug discovery in Alzheimer's disease. Alzheimers Dementia: Alzheimer's Assoc 4(2): 80-8 (2008).